Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hydralazine × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4 Breast 2 Thoracic 1 Other solid neoplasm 1 Gastrointestinal 1

Conditions

Rectal Neoplasms 1

Interventions

Oxaliplatin 1286 Fluorouracil 1188 Capecitabine 982 Gemcitabine 934 Leucovorin 845 Bevacizumab 748 Irinotecan 744 Cisplatin 601 Radiotherapy 513 Cetuximab 426 pembrolizumab 389 Paclitaxel 357 Drug Therapy 320 Nivolumab 308 130-nm albumin-bound paclitaxel 283 Docetaxel 263 Sorafenib 261 S 1 (combination) 255 Folfox protocol 240 Surgical Procedures, Operative 228 Albumin-Bound Paclitaxel 227 durvalumab 195 lenvatinib 194 apatinib 187 tislelizumab 186 sintilimab 182 regorafenib 179 Radiosurgery 177 Neoadjuvant Therapy 174 Magnetic Resonance Spectroscopy 174

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00575640 2015-03-04

Hydralazine as a Demethylating Agent in Rectal Cancer

University of Arkansas

Phase 1/2 Withdrawn

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡